The latest price target for Bicycle Therapeutics (NASDAQ:BCYC) was reported by Oppenheimer on March 18, 2026. The analyst firm set a price target for $36.00 expecting BCYC to rise to within 12 months (a possible 735.27% upside). 19 analyst firms have reported ratings in the last year.

The latest analyst rating for Bicycle Therapeutics (NASDAQ:BCYC) was provided by Oppenheimer, and Bicycle Therapeutics maintained their outperform rating.

The last upgrade for Bicycle Therapeutics PLC happened on September 12, 2023 when B. Riley Securities raised their price target to $33. B. Riley Securities previously had a neutral for Bicycle Therapeutics PLC.

The last downgrade for Bicycle Therapeutics PLC happened on October 31, 2025 when RBC Capital changed their price target from $27 to $11 for Bicycle Therapeutics PLC.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bicycle Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bicycle Therapeutics was filed on March 18, 2026 so you should expect the next rating to be made available sometime around March 18, 2027.

While ratings are subjective and will change, the latest Bicycle Therapeutics (BCYC) rating was a maintained with a price target of $44.00 to $36.00. The current price Bicycle Therapeutics (BCYC) is trading at is $4.31, which is out of the analyst’s predicted range.